The Absolute Dosage Illusion: The Difference Between What You Ingest and What You Absorb

A supplement manufacturer can print "500 mg of magnesium" on its label. That is legally accurate. It is biologically misleading.

The question is not how much you swallow. The question is how much of that amount crosses the intestinal wall, reaches the bloodstream, and ultimately enters your cells. That journey, from capsule to mitochondria, is governed by a single factor: the molecular form of the bioactive.

Gastric dissolution: the first barrier, the first selection

Everything begins in the stomach. For a mineral to be absorbable, it must first dissolve in the acidic gastric environment and be released as soluble ions or complexes. This is where molecular forms diverge radically.

Magnesium oxide (MgO) is one of the most magnesium-dense forms, which explains its prevalence in budget supplements. But oxide is a strong base. At normal gastric pH, its solubility is very low. The dissolved, and therefore potentially absorbable, fraction remains small. A randomized double-blind study by Walker et al. confirmed that magnesium citrate led to significantly higher serum magnesium concentrations than oxide, all other factors being equal (PubMed).

Citrate, malate, and glycinate are organic forms. They dissolve more readily in an acidic environment, release magnesium in a controlled manner, and present a significantly more favorable absorption profile.

Intestinal transport: passive or active, the form decides

Once dissolved, minerals and vitamins must cross the intestinal epithelial barrier. Two mechanisms coexist: passive diffusion, where the nutrient naturally moves from a more concentrated area to a less concentrated one, and active transport, which relies on specific carrier proteins to shuttle the nutrient into the cell.

Magnesium oxide releases free Mg²⁺ ions. These ions primarily use the passive route, which has limited efficiency and becomes saturated at relatively low doses. Magnesium diglycinate, by contrast, presents itself as a complex where the mineral is bound to an amino acid (glycine). A portion of this complex is absorbed intact via dipeptide transporters (PEPT1, intestinal gateways designed for small protein fragments), a high-capacity pathway (PubMed). This is precisely the mechanism that explains the advantage of chelated forms (where the mineral is "wrapped" in an amino acid), particularly in individuals with reduced intestinal absorption capacity.

The same principle applies to iron. Ferrous sulfate (FeSO₄), the standard form in many iron supplements, generates free Fe²⁺ ions that trigger local oxidative stress in the intestinal mucosa. The result: nausea, constipation, abdominal pain, and ultimately poor compliance. Iron bisglycinate is a stable chelated complex. It uses the same transport pathways as amino acids, bypasses classic inhibition mechanisms (phytates and polyphenols, plant compounds that trap minerals and reduce their absorption), and demonstrates markedly superior digestive tolerability (PubMed). A clinical trial in infants with iron-deficiency anemia measured bioavailability of 90.9% for iron bisglycinate versus 26.7% for ferrous sulfate (PubMed).

Folate and the MTHFR polymorphism: when form determines conversion

Folic acid is the synthetic form of folate. It is ubiquitous in supplements and fortified foods. But folic acid is not folate: it is a precursor that must be converted into 5-methyltetrahydrofolate (5-MTHF), the biologically active form, by an enzyme called MTHFR (methylenetetrahydrofolate reductase).

Approximately 10 to 15% of the European population carries two identical copies of a variant in the MTHFR gene (known as a homozygous carrier of the C677T or A1298C polymorphism). In these individuals, the enzyme works less efficiently and the conversion of dietary folate into 5-MTHF is slowed.

One point deserves to be made straight away, because it is almost always left out: the advantage of methylfolate is not confined to them. In the crossover trial that compared the two forms in the same women, at equivalent amounts, that advantage is the same in homozygous carriers and in non-carriers. What actually separates the two forms lies elsewhere: folic acid regularly leaves an unmetabolized fraction in plasma, something rarely seen with methylfolate (PubMed).

5-MTHF (methylfolate) is already the form in which folate circulates in plasma: it no longer has to be reduced by MTHFR. It then donates its methyl group through methionine synthase, a reaction that depends on vitamin B12. A randomized controlled trial in 54 adults selected on their genotype measured, under a combination of methylfolate, pyridoxal-5'-phosphate and methylcobalamin, a 48.3% reduction in homocysteine in homozygous carriers, against 18.6% in mixed allele carriers (PubMed). As the three vitamins were given together, the effect there cannot be attributed to any one of them on its own.

Displaying "400 µg of folate (folic acid)" without specifying the form remains incomplete information, and it is so for everyone: the form determines what actually reaches the plasma.

Cyanocobalamin and methylcobalamin: same vitamin, different fate

Cyanocobalamin is the least expensive form of vitamin B12 to produce. It is stable, low in reactivity, and constitutes the majority of budget supplements. To become biologically active, it must shed its cyanide radical and be converted into methylcobalamin or adenosylcobalamin, the active coenzyme forms.

This conversion is often presented as the step that methylcobalamin would spare. The available literature says otherwise. Every ingested form, coenzyme forms included, is handled by the same escort protein, present in the cytoplasm of every cell. It brings them back to a common cobalamin core, after which the active forms are rebuilt (PubMed). The methyl group supplied by a methylcobalamin supplement is cleaved on entry into the cell and is not used to build intracellular methylcobalamin (PubMed).

One serious reason to set cyanocobalamin aside remains, and it concerns safety. An individual-patient meta-analysis of two large stroke-prevention trials separated participants by renal function. Those whose function is impaired and who receive high-dose cyanocobalamin draw no benefit from B vitamin therapy. Those whose function is normal benefit significantly (PubMed).

Hepatic first-pass metabolism is another barrier that is often overlooked. Certain molecules, once absorbed by the intestine, pass through the portal circulation (the blood network connecting the gut to the liver) and reach the liver before entering general circulation. The liver can modify, conjugate, or destroy a significant fraction of these molecules. The molecular form partly determines the extent of this effect.

When a well-absorbed nutrient blocks another

Bioavailability does not operate in isolation. Each nutrient enters an ecosystem where intestinal transporters are shared and metabolic pathways interconnected. A perfectly absorbed bioactive can, by its very presence, compromise the assimilation of another.

The most documented case is the zinc-copper antagonism. Both minerals share the same intestinal absorption pathways. At high zinc intakes, metallothionein (a metal-trapping protein) production in enterocytes (the cells lining the intestinal wall) increases, sequestering dietary copper before it reaches circulation (PubMed). In practice: a perfectly bioavailable zinc supplement, taken in isolation without adjustment, can cause progressive copper depletion. Form is not enough. The administration context and ratios between nutrients matter as much as the molecule itself.

The reverse also exists: some combinations involve complementary physiological steps. Vitamin D contributes to normal absorption/utilisation of calcium and phosphorus. Vitamin K enables the carboxylation of proteins such as osteocalcin and matrix Gla protein (PubMed). These mechanisms explain their frequent pairing in formulations, without showing that K2 is clinically indispensable with every D3 intake or that it directs calcium away from arteries.

A supplement can display spectacular doses and deliver very little. Another, more modest in its communication, can achieve real biological efficacy through a correctly selected form and well-calibrated nutrient ratios. A recent comparative study on different magnesium forms illustrates this clearly: microencapsulated magnesium maintained sustained plasma elevation over six hours, whereas oxide produced only an early, transient peak (PubMed).

The next frontier in supplementation is not dosage, but form, interactions, and the understanding of cellular absorption mechanisms that distinguishes a rigorous approach from a marketing strategy.

Frequently asked questions

Why does the dosage on a supplement label not reflect what the body actually absorbs?#[ + ]

The label dosage indicates the quantity ingested, not the quantity absorbed. Between the two, the bioactive must dissolve in the stomach, cross the intestinal barrier, and survive hepatic first-pass metabolism. The molecular form determines the efficiency of each step, with differences reaching a factor of ten or more.

What is the difference between magnesium oxide and magnesium bisglycinate?#[ + ]

Magnesium oxide dissolves poorly in gastric acid and releases free Mg2+ ions that use a passive absorption pathway with limited capacity: a comparison of commercial preparations measures it at approximately 4% fractional absorption. Bisglycinate is a chelated complex, a fraction of which appears to be absorbed intact through a peptide transport pathway. No direct human comparison places it above the other organic forms, however; its established difference concerns digestive tolerance.

What is the MTHFR polymorphism and why does the form of folate matter?#[ + ]

The C677T variant of the MTHFR gene is carried in homozygous form by roughly 10 to 15% of the European population. In these individuals the enzyme works less efficiently and the conversion of folate into its active form is slowed. The trial that compared methylfolate with folic acid in the same women nonetheless finds the same advantage in both genotypes. What separates the two forms is the amount of unmetabolized folic acid left in plasma, lower with methylfolate.

Can a supplement prevent the absorption of another nutrient?#[ + ]

Yes. The most documented example is zinc-copper antagonism: at high doses, zinc stimulates metallothionein production in intestinal cells, which traps copper before it reaches circulation. Conversely, some combinations are synergistic: vitamin D3 increases calcium absorption, and vitamin K2 carboxylates osteocalcin, the protein that binds that calcium to the bone matrix.

Why does increasing the dose of a poorly absorbable supplement not solve the problem?#[ + ]

If only 4 to 10% of a poorly bioavailable form reaches circulation, increasing the raw dose does not fundamentally compensate for the absorption deficit. Excess free ions in the colon can cause digestive discomfort and interfere with the assimilation of other nutrients. It is the molecular form, not the quantity, that determines real biological efficacy.

---

References

1. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res. 2003;16(3):183-91 (PubMed).
2. Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN J Parenter Enteral Nutr. 1994;18(5):430-5 (PubMed).
3. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435-43 (PubMed).
4. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381-4 (PubMed).
5. Prinz-Langenohl R, Bramswig S, Tobolski O, et al. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C>T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol. 2009;158(8):2014-21 (PubMed).
6. Pokushalov E, Ponomarenko A, Bayramova S, et al. Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin Supplementation on Homocysteine and LDL-C in Patients with MTHFR, MTR, and MTRR Polymorphisms. Nutrients. 2024;16(11):1550 (PubMed).
7. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Mol Nutr Food Res. 2015;59(7):1364-72 (PubMed).
8. Paul C, Brady DM. Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms. Integr Med (Encinitas). 2017;16(1):42-9 (PubMed).
9. Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol. 2017;16(9):750-60 (PubMed).
10. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am J Clin Nutr. 1995;61(3 Suppl):621S-624S (PubMed).
11. van Ballegooijen AJ, Pilz S, Tomaschitz A, Grübler MR, Verheyen N. The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review. Int J Endocrinol. 2017;2017:7454376 (PubMed).
12. Pajuelo D, Meissner JM, Negra T, Connolly A, Mullor JL. Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium Versus Other Magnesium Sources. Nutrients. 2024;16(24):4367 (PubMed).